

# **Recent advances in the treatment of diabetic Macular edema**

Essay Submitted for partial fulfillment of MSc degree in  
ophthalmology  
by

**Heba Abu AlhemamAlkenany**

M B BCh

Supervised by

**Prof.Dr. Ahmed Ibrahim Abu Alnaga**

Professor of ophthalmology

Faculty of Medicine-Ain Shams University

**Dr. Mohamed Ramadan Mohamed**

Lecture of ophthalmology

Faculty of Medicine-Ain Shams University

Ain Shams University  
Cairo-2013

# **Acknowledgment**

**It is indeed an honor to me to be supervised by Prof. Dr Ahmed Abu Alnaga, Professor of Ophthalmology, Ain Shams University, who was so really so supportive & helpful to me in this study.**

**And I am really grateful to Dr.Mohmed Ramadan, lecture of Ophthalmology, Ain Shams University for his valuable advices and continuous effort and his guidance to me throughout this study.**

## **AIM OF WORK**

The aim of this work is to highlight advantages and disadvantages & differentiate advanced modalities in management of diabetic macular edema

# Introduction

Diabetic retinopathy is a microangiopathy affecting the retinal precapillary arterioles, capillaries & venules, however large vessels may also be involved. Retinopathy has features of both microvascular occlusion & leakage.<sup>1</sup>

Diabetic macular edema, the leading cause of visual loss in diabetic retinopathy. DME, whether focal or diffuse can be characterized as a retinal thickening within 2 disc diameters of the center of the macula. Breakdown of the blood-retinal barrier with leakage from microaneurysms, retinal capillaries, and arterioles all contribute to DME.<sup>2</sup>

Poor control of blood sugar, renal disease, systemic hypertension, and elevated lipid levels all increase the risk of DME. Current understanding of the epidemiologic features and disease burden of DME is limited.<sup>3</sup>

There is still no proven intervention that prevents or reverses visual loss from diabetic macular edema in all patients. A variety of promising new medical & surgical procedures are under investigation, but more research is required to determine their role alone or in combination.<sup>4</sup>

The standard guidelines for focal laser photocoagulation for DME have been provided by the ETDRS. Direct treatment to leaking microaneurysms and grid treatment of diffuse macular edema or non-perfused thickened retina have been suggested for mild and moderate NPDR.<sup>5</sup>

Despite timely and appropriate use of laser, some patients continue to experience visual loss. The pathogenesis of PDR and DME is multifactorial involving both angiogenic and inflammatory processes. Recent trials have shown that the anti-inflammatory and anti-angiogenic properties of corticosteroids may provide benefit in treating PDR and DME.<sup>6,7,8</sup>

The clinical outcomes and complications of intravitreal corticosteroid injection have been described in several animal and human studies. Intravitreal triamcinolone acetonide (1--8 mg) has been used to treat DME. The most common ocular side effects attributed to corticosteroids are glaucoma and cataract. In addition, endophthalmitis and retinal detachment may complicate intravitreal injections. <sup>9 10</sup>

VEGF-A is a major mediator of increased retinal permeability. Blockage of VEGF has shown to reduce vascular permeability. VEGF inhibition has been achieved via PKC inhibitors as well as high affinity binding of either aptamers (e.g., protein kinase C inhibitor, pegaptanib) or antibodies (e.g., ranimizumab, bevacizumab) targeted against VEGF-A. Specific drug treatments are likely to become available for macular edema. <sup>11</sup>

There is clinical evidence that both tractional and non-tractional factors at the vitreoretinal interface play an important role in the pathogenesis of macular edema. Many hypotheses exist regarding how vitrectomy may improve DME. Induction of posterior vitreous detachment, removal of taut posterior cortex, removal of ILM, and a complete pars plana vitrectomy have been reported to resolve DME. <sup>12 13</sup>

## References of introduction;

1. Jack J Kanski, Clinical ophthalmology, systemic approach, Elsevier chapter .XVI. Diabetic retinopathy. 2007; 566-624.
2. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 1. Arch Ophthalmol 1985;103:1796–806
3. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102:7–16.
4. Wolter Kluwer Health Lippincott Williams, Wilkins Curr Opin Ophthalmology. 2008;185 (19 ) 8040-8738.
5. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic study of Diabetic Retinopathy, IV: diabetic macular edema. Ophthalmology. 1984;91:1464--74
6. Paolo S., Sun, Jennifer K. and Aiello, Lloyd Paul 'Role of Steroids in the Management of Diabetic Macular Edema and Proliferative Diabetic Retinopathy', Seminars in Ophthalmology (2009), 24:2, 93 — 99.
7. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991;98(10):1594--602
8. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920—7
9. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmology. 2001; 29(1):2--6

10. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. *Ophthalmology*. 2001; 108(4):765--728.
11. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling—in control of vascular function. *Nat Rev Mol Cell Biol*. 2006;7(5):359—71
12. Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. *Surv Ophthalmology*. 2006;51(4):364—80
13. Stefansson E, Landers MBI, Wolbarsht ML. Increased retinal oxygen supply following panretinal photocoagulation and vitrectomy and lensectomy. *Trans Am Acad Ophthalmol Soc*. 1981;79:307--34

# **Contents**

## **First chapter; simple anatomy of the retina**

- 1. overview**
- 2. central and peripheral retina compared**
- 3. Muller glial cells**
- 4. Foveal structure**
- 5. Macula lutea**
- 6. Blood supply to the retina**

## **Second chapter; Pathogenesis of Diabetic Macular Edema**

### **A. Blood Retinal Barrier**

- 1. Inner blood retinal barrier**
  - a. Glial cells**
  - b. Pericytes**
  - c. Retinal vascular endothelial cells**
  - d. Retinal vessel leukostasis**
  - e. Advanced Glycation End Products**
- 2. Outer blood retinal barrier**

### **B. Role of vasoactive factors**

- 1. Vascular Endothelial Growth Factors**
- 2. Protein Kinase C**
- 3. Histamine**
- 4. Angiotensin II**
- 5. Matrix Metalloproteases**
- 6. Pigment Epithelial Derived Factor**
- 7. Platelet derived Growth Factor**
- 8. Basic fibroblast Growth Factor**

### **C. Vitreoretinal interface**

- 1. Posterior Vitreous Detachment**
- 2. Posterior Cortical Vitreous**
- 3. Thickened and Taut Posterior Hyaloid**

- 4. Macular Traction in Proliferative Diabetic Retinopathy**
- 5. Role of Internal Limiting Membrane**
- 6. Role of Vitreous Gel**

**D. Others**

**Third Chapter; Diagnosis of Diabetic Macular Edema**

- A. Epidemiology**
- B. Clinical Picture**
- C. Investigations**

- 1. Fluorescein Angiography**
- 2. Optical Coherence Tomography**
- 3. Retinal Thickness Analyser**
- 4. Laboratory Investigations**

**Fourth Chapter; Treatment modalities for Diabetic Macular Edema**

- 1. Laser Photocoagulation**
  - a. Focal**
  - b. Grid**
  - c. Modified Grid**
  - d. Micro pulse Diode**
- 2. Intra Vitreal Injections**
  - a. Steroids**
  - b. Anti Angiogenic**
  - c. Anti Tumor Necrotic Factors**
- 3. Pars Plana Vitrectomy**
- 4. Combination Therapy**
- 5. Posterior subtenon Steroid Injection**
- 6. Extended Release Corticosteroid Delivery System**
- 7. Systemically Administered Medications**
- 8. Topical Non Steroidal Anti Inflammatory Drugs and Carbonic anhydrase inhibitor**
- 9. Other agents**
- 10. Medical Therapy**

## List of Figures:

<b>Figure No.</b>	<b>Figure Title</b>	<b>Page No.</b>
<b>1.</b>	<b>Retina as seen through an ophthalmoscope</b>	<b>2</b>
<b>2.</b>	<b>Simple organization of the retina</b>	<b>2</b>
<b>3.</b>	<b>Light micrograph of a vertical section through human central retina</b>	<b>3</b>
<b>4.</b>	<b>Light micrograph of a vertical section through human peripheral retina</b>	<b>3</b>
<b>5.</b>	<b>Vertical view of Golgi stained Muller glial cells</b>	<b>4</b>
<b>6.</b>	<b>Vertical section of the human fovea</b>	<b>5</b>
<b>7.</b>	<b>Anatomical explanation of diffuse &amp; cystoids macular edema</b>	<b>6</b>
<b>8.</b>	<b>Blood supply of the retina</b>	<b>8</b>
<b>9.</b>	<b>Pathogenesis of diabetic macular edema. AII angiotensin II; AGE advanced glycation end products; DAG diacylglycerol; ET endothelin; LPO lipoxygenase; NO nitric oxide; PKC protein kinase C; RAS renin angiotensin system; VEGF vascular endothelial growth factor MMP matrix metalloproteinase</b>	<b>10</b>
<b>10.</b>	<b>Inner &amp; Outer BRB</b>	<b>11</b>
<b>11.</b>	<b>Inner BRB</b>	<b>12</b>
<b>12.</b>	<b>Inner BRB</b>	<b>13</b>
<b>13.</b>	<b>Role of leukostasis in DR</b>	<b>14</b>
<b>14.</b>	<b>Role of AGEs in DR</b>	<b>15</b>
<b>15.</b>	<b>outer BRB</b>	<b>16</b>

16.	<b>Angiogenesis Stimulators and Inhibitors</b>	<b>17</b>
17.	<b>VEGF receptors on blood vessel wall</b>	<b>18</b>
18.	<b>Glycolysis in DR</b>	<b>19</b>
19.	<b>Schematic drawing of the posterior precortical vitreous pocket (PPVP)</b>	<b>22</b>
20.	<b>OCT shows a taut posterior hyaloid in a patient with diabetic retinopathy.</b>	<b>23</b>
21.	<b>OCT image of normal and swollen macula</b>	<b>24</b>
22.	<b>Peeling of ILM</b>	<b>25</b>
23.	<b>Graph plotting prevalence of diabetic retinopathy complications against the risk of duration</b>	<b>27</b>
24.	<b>colored photo as seen by normal subject and by one how have diabetic retinopathy the last one suffering from blurring and multiple scotomas</b>	<b>28</b>
25.	<b>Fundus colored photo showing types of clinically significant macular edema</b>	<b>29</b>
26.	<b>Focal diabetic macular edema. Left: Fundus photo of the left eye with a circinate ring of hard exudates surrounding microaneurysms in the macula. Right: fluorescein angiography shows hyperfluorescent punctate lesions,leaking microaneurysms in the center of the circinate ring</b>	<b>31</b>
27.	<b>Diffuse diabetic macular edema. Left: Fundus photo of the left eye with old grid laser scars with clinically significant macular edema. Right: Fluorescein angiography shows leakage throughout the posterior pole from ischemic capillary beds</b>	<b>31</b>
28.	<b>Ischemic macula</b>	<b>32</b>
29.	<b>Normal macular thickness map in OCT according to age</b>	<b>33</b>
30.	<b>(a); Spongy, thick or diffuse macular edema on OCT</b>	<b>33</b>
	<b>(b); Cystoid macular edema with neurosensory</b>	<b>34</b>

	<b>detachment</b>	<b>35</b>
	<b>© Macular edema with vitreomacular traction</b>	
<b>31.</b>	<b>Out paper print of left eye macular cube by Cirrus OCT</b>	<b>36</b>
<b>32.</b>	<b>Retinal thickness analyser map</b>	<b>37</b>
<b>33.</b>	<b>Hard exudates in posterior pole</b>	<b>40</b>
<b>34.</b>	<b>Showing modified grid laser for diffuse diffuse maculopathy</b>	<b>43</b>
<b>35.</b>	<b>Micropulse diode laser</b>	<b>44</b>
<b>36.</b>	<b>Micropulse diode laser</b>	<b>44</b>
<b>37.</b>	<b>Chemical structure of Triamcinolone</b>	<b>46</b>
<b>38.</b>	<b>Colored photo and B-scan images showing IVTA crystals floating in vitreous</b>	<b>48</b>
<b>39.</b>	<b>Comparison of the clinical course between the triamcinolone acetate injected eyes (closed circle) and the bevacizumab injected eyes (open circle) in patients with bilateral diabetic macular edema (DME). (Top) Comparison of the clinical course of foveal thickness. Each point and vertical bar indicates mean foveal thickness <math>\pm</math> standard deviation (SD) of the mean. (Bottom) Comparison of the clinical course of logarithm of the minimum angle of resolution (logMAR) visual acuity (VA). Each point and vertical bar indicates mean logMAR VA <math>\pm</math> SD of the mean. The asterisk (*) indicates a statistically significant difference between the triamcinolone- and bevacizumab- injected eyes at each time point (<math>P &lt; .05</math>).</b>	<b>52</b>
<b>40.</b>	<b>Clinical course of delta intraocular pressure (<math>\Delta</math>IOP) after the intravitreal injection of triamcinolone acetate (open circle), and bevacizumab (closed circle) eyes in patients with bilateral DME. The vertical bar indicates SD of the mean. <math>\Delta</math>IOP in the triamcinolone-injected eye showed a significant increase in each time point, in contrast <math>\Delta</math>IOP in the bevacizumab-injected eye did not change significantly. The asterisk (*) indicates statistical significance (<math>P &lt; .05</math>).</b>	<b>53</b>

41.	OCT out paper print, comparison of time respond to IVTA and IVAI	54
42.	Time against vision and macular thickness comparing Lucentis with laser and combined	56
43.	Koch study of combined treatment vitrectomy, laser and anti VEGF	59
44.	Diagram showing site of injection subtenon and intravitrous	60
45.	Fluocinoloneacetone (FA) sustained –delivery device.	63
46.	from left to right,Aldosereductaseinhibitor,Fenofibrate,Ruboxistaurin, Candesartan,Aspirin	63
47.	from left to right chemical structure of Nepfenac , Acetazolamide &Bromfenac.	65
48.	Treatment algorithm of DME	70

## List of Abbreviations:

AII                      Angiotensine II

AGEs	Advanced Glucation End Products
b-FGF	Basic fibroblast growth factor
BRB	Blood Retinal Barrier
CAI	Carbonic anhydrase inhibitors
CME	Cystoid Macular Edema
CSME	Clinical Significant Macular Edema
DAG	Diacylglycerol
DCCT	Diabetic control and complication s trial
DIRECT	Diabetic retinopathy candesartan trials
DME	Diabetic Macular Edema
DRCR	Diabetic Retinopathy Clinical Research Network
ET-1	Endothelin
ETDRS	Early treatment diabetic retinopathy study
ELM	External Limiting Membrane
FA	Fluocinoloneacetoneid
FAME	Fluocinolone medical evaluation
FAZ	Foveal A vascular Zone
FDA	Food and Drug Administration
FFA	Flourosine Angiography
FGF-2	Fibroblast growth factor-2
GCL	Gangelion cell layer
GDNF	Glial cell derived neurotropic factor
GFAP	Glial fibrillary acidic protein
ICAM-1	Intra cellular adhesion molecule-1
IGF	Insulin Growth Factor
IL-1	Inter leukin-1

ILM	Internal Limiting Membrane
INL	Inner Nuclear Layer
IOP	Intra Ocular Pressure
IRMA	Intra retinal micro vascular abnormalities
IVTA	Intra vitreal triamcinolone
MAPK	Mitogen activated protein kinase
mm	Millimeter
MMPS	Matrix metalloproteinase
μs	Microsecond
mw	Milli watt
NFL	Nerve fibre layer
nm	Nanometer
NSAIDs	Non Steroidal Anti-Inflammatory Drugs
OCT	Ocular Coherence Tomography
ONL	Outer Nuclear Layer
OPL	Outer plexiform Layer
PC	Phosphatidylcholine
PDGF	Platelet derived growth factor
PDR	Proliferative diabetic retinopathy
PEDF	Pigment epithelium derived factor
PKC	Protein Kinase c
PPV	Pars plana vitrectomy
PPVP	Posterior precortical vitreous pocket
PST	Posterior subtenon
PVD	Posterior vitreous detachment
RAS	Renin angiotensin system